QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 26 May 2022Portfolio NewsAlchemab appoints Young T. Kwon as Chief Executive Officer
- 25 May 2022Portfolio NewsPrilenia Announces Publication of Data Elucidating a Mechanism for Neuroprotective Potential of Pridopidine
- 27 April 2022Portfolio NewsAviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia
- 19 April 2022Portfolio NewsCerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
- 12 April 2022Portfolio NewsSitryx Therapeutics Strengthens Leadership Team With Appointment of Ravi M. Rao as Chief Medical Officer
- 12 April 2022Portfolio NewsSV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
- 10 April 2022SV NewsLife Sciences Summit: venture capital plugs gap in funding
- 5 April 2022Portfolio NewsCatamaran Bio Appoints Frank Lee as Chair of its Board of Directors
- 5 April 2022Portfolio NewsNitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research
- Video31 March 2022SV NewsKate Bingham interviewed by Beth Rigby, Sky News, on the lessons learnt from the UK Vaccine Taskforce
- 31 March 2022Portfolio NewsCerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
- Video30 March 2022SV NewsKate Bingham shared the key lessons learnt from the success of the UK Vaccine Taskforce at The Royal Society’s recent Science of COVID-19 event.